Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia. NICE technology appraisal guidance 1185
National Institute for Health and Care Excellence (NICE)
Record ID 32018015936
English
Details
Project Status:
Completed
URL for project:
https://www.nice.org.uk/guidance/ta1185
Year Published:
2026
URL for published report:
https://www.nice.org.uk/guidance/ta1185
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England
MeSH Terms
- Antineoplastic Combined Chemotherapy Protocols
- Leukemia, Lymphocytic, Chronic, B-Cell
- Antineoplastic Agents
- Tyrosine Kinase Inhibitors
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents, Immunological
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
3rd floor, 3 Piccadilly Place, Manchester, M1 3BN
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.